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Abstract
Infection imposes a serious burden on patients with systemic
lupus erythematosus (SLE). The increased infection rate in SLE
patients has been attributed in part to defects of immune
defence. Recently, the lectin pathway of complement activation
has also been suggested to play a role in the occurrence of
infections in SLE. In previous studies, SLE patients homozygous
for mannose-binding lectin (MBL) variant alleles were at an
increased risk of acquiring serious infections in comparison with
patients who were heterozygous or homozygous for the normal
allele. This association suggests a correlation between
functional MBL level and occurrence of infections in SLE
patients. We therefore investigated the biological activity of
MBL and its relationship with the occurrence of infections in
patients with SLE. Demographic and clinical data were
collected in 103 patients with SLE. Functional MBL serum levels
and MBL-induced C4 deposition were measured by enzyme-
linked immunosorbent assay using mannan as coat and an MBL-
or C4b-specific monoclonal antibody. The complete MBL-
dependent pathway activity was determined by using an assay
that measures the complete MBL pathway activity in serum,
starting with binding of MBL to mannan, and was detected with
a specific monoclonal antibody against C5b-9. Charts were
systematically reviewed to obtain information on documented
infections since diagnosis of SLE. Major infections were defined
as infections requiring hospital admission and intravenous
administration of antibiotics. In total, 115 infections since
diagnosis of lupus, including 42 major infections, were
documented in the 103 SLE patients (mean age 41 ± 13 years,
mean disease duration 7 ± 4 years). The percentage of SLE
patients with severe MBL deficiency was similar to that in 100
healthy controls: 13% versus 14%, respectively. Although
deposition of C4 to mannan and MBL pathway activity were
reduced in 21% and 43% of 103 SLE patients, respectively,
neither functional MBL serum levels nor MBL pathway activity
was associated with infections or major infections in regression
analyses. In conclusion, SLE patients frequently suffer from
infections, but deficiency of functional MBL does not confer
additional risk.
Introduction
Infections are an important cause of morbidity and mortality in
patients with systemic lupus erythematosus (SLE). Infectious
complications occur in 25% to 45% of SLE patients in case
series [1,2], and infection as cause of death has been reported
in up to 50% of patients with SLE [3,4]. The increased infec-
tion rate in patients with SLE has been attributed in part to
defects in the complement system, which has an important
role in host defence against microorganisms [3].
Genetic deficiencies of early components of the classical
pathway of complement activation are strongly associated
with the development of SLE [5]. In particular, deficiency of
C1q is a major predisposing risk factor for SLE. C1q plays a
role in the recognition and clearance of apoptotic material [6]
and binds predominantly to antibodies and protein structures
on bacteria and viruses, resulting in complement activation.
More recently, the lectin pathway of complement activation
has also been suggested to play a role in the pathogenesis of
HRP = horseradish peroxidase; MASP = mannose-binding lectin-associated serine protease; MBL = mannose-binding lectin; SLE = systemic lupus 
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SLE [7] and in the occurrence of infections in SLE [8-10].
Mannose-binding lectin (MBL) is a serum protein with charac-
teristics very similar to those of C1q [11]. MBL may activate
complement through the lectin pathway by interacting with
MBL-associated serine proteases (MASPs). Furthermore,
MBL can directly opsonise pathogens and enhance the activ-
ity of phagocytes [12].
Homozygosity for variant MBL alleles is probably a minor risk
factor for the presence of SLE, as shown by a recent meta-
analysis of all available case-control studies. In that study, a
significant association between MBL codon 54 variant B and
SLE was demonstrated [13]. Genetic and phenotypic defi-
ciency in producing MBL has been associated with recurrent
or serious infections, mainly in children [14] and in immune-
compromised individuals [15].
In three previous studies, SLE patients homozygous for MBL
variant alleles were at an increased risk for serious infections
compared with patients who were heterozygous or
homozygous for the normal allele [8-10]. This association sug-
gests a correlation between functional MBL level and occur-
rence of infections in these patients. However, the association
between rates of infection and functional MBL serum levels
has not been studied yet.
Genotype predicts MBL serum concentration reasonably well
at the population level. However, in individuals, even full geno-
typic characterisation is insufficient to predict functional MBL
serum levels [16,17]. Moreover, functional MBL serum levels
not only are determined by MBL genotype and promoter poly-
morphisms but also are influenced by MASP activity and
serum levels of other complement factors. Assays are available
to test these separate influences [18]. The capacity of highly
oligomerised MBL to bind to microorganisms can be tested in
vitro by incubating serum on mannan-coated plates and sub-
sequently detecting bound MBL with an MBL-specific mono-
clonal antibody. This assay is dependent only on the amount of
functional MBL protein. Activity of the MBL/MASP complex is
determined by performing the incubation on mannan-coated
plates at 37°C and subsequently detecting C4 deposition on
the surface. Functional MBL serum levels and C4 deposition
are highly correlated except in cases of MASP deficiency.
Functional activity of the entire MBL pathway can be measured
starting with binding of MBL to mannan and detection of the
membrane-attack complex C5–9. This assay is sensitive to
defects in all components of the MBL pathway. Following the
above methodology, we measured functional MBL activity in
our clinic population of patients with SLE and related this to
past infectious events.
Materials and methods
Patients and data collection
One hundred and three patients fulfilling the revised criteria for
the classification of SLE [19] were included in the study. All
patients were regular outpatients of the rheumatology clinic of
the VU University Medical Center, the Jan van Breemen Insti-
tute, or the Slotervaart Hospital. These clinics provide primary
through tertiary care for patients with SLE in Amsterdam, The
Netherlands. The local ethics committee approved the study.
All patients provided informed consent for their participation.
Demographic, patient, and disease characteristics were sys-
tematically recorded by interview, self-reported questionnaire,
chart review, and clinical examination performed by one rheu-
matologist (IEMB).
Definition of infections
Infections were included in the analysis if they met the follow-
ing criteria: documentation in medical records (patient charts
and microbiology laboratory reports), occurring since diagno-
sis of lupus, and confirmed both by clinical findings and posi-
tive cultures. If bacterial isolates were not available (for
example, in some cases of pneumonia, sinusitis, and otitis),
infection was diagnosed by clinical manifestations in combina-
tion with radiographic findings and response to antibiotic treat-
ment. Lower urinary tract infections were excluded because of
potential under-reporting of this infection. Viral infections were
included if clinical symptoms of a viral infection were present
in combination with positive culture or confirmed by high titres
of antibodies for virus-specific antigens. Herpes zoster infec-
tions were included if typical dermatomal vesicular cutaneous
lesions had occurred. Major infections were defined as infec-
tions for which hospital admission and intravenous antibiotic
treatment had been required. Opportunistic infections were
defined as infections with pathogens that are uncommon in
the non-compromised host.
Laboratory investigations
Assessment of functional MBL serum levels and C4 
concentration
Fifty micrograms per millilitre of mannan (Sigma-Aldrich, St.
Louis, MO, USA) was coated overnight in coating buffer (0.1
M carbonate, pH 9.6) on a Nunc Maxisorp microtitre plate (Inv-
itrogen, Breda, The Netherlands). All incubations were per-
formed in a volume of 100 μl at room temperature. Plates were
washed five times with water (all other washes were also car-
ried out in water), and samples were diluted 1:3, 1:9, 1:27,
and 1:81 in TTG/Ca2+ (20 mM Tris, 150 mM NaCl, 0.2% gel-
atin [wt/vol], 0.02% TWEEN-20 [wt/vol], 10 mM CaCl2, pH
7.4) for 1 hour. A standard curve was generated using two-
fold serial dilutions of a pool of 3,000 sera obtained from blood
bank donors, containing 1.5 μg/ml of MBL when compared
with a standard from Dade Behring Holding GmbH (Eschborn,
Germany). Plates were washed five times and incubated with
2 μg/ml of biotinylated CLB-MBL/1 in TTG/Ca2+ for 1 hour.
After washing five times, the plates were incubated with
polymerised streptavidin-horseradish peroxidase (HRP) (San-
quin, Amsterdam, The Netherlands) diluted 1:10,000 in Tris-
buffered saline/Ca2+/milk (20 mM Tris, 150 mM NaCl, 10 mM
CaCl2, 2% [vol/vol] cow's milk, pH 7.4). Plates were incubatedAvailable online http://arthritis-research.com/content/8/6/R183
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for 30 minutes and washed five times. The assay was devel-
oped with 100 μg/ml TMB (3,3',5,5'-tetramethylbenzidine) in
0.11 M sodium acetate (pH 5.5) containing 0.003% H2O2
(vol/vol). Substrate conversion was stopped by adding 100 μl
of 2 M H2SO4, and absorbance was measured at 450 nm. The
assay was validated by testing 100 blood bank donors using
either CLB-MBL/1 as described above or HYB 131-1 (a kind
gift of S. Thiel, University of Aarhus, Aarhus, Denmark), which
revealed comparable results. A cutoff value of less than 0.05
μg/ml MBL corresponds to low-level-producing MBL geno-
types [16]. Serum levels of C4 were measured by nephelom-
etry (Dade Behring Holding GmbH).
Assessment of MBL-induced C4 deposition on mannan
Plates were coated overnight in coating buffer with 50 μg/ml
of mannan. All incubations were performed in a volume of 100
μl. Serum samples were diluted 1:10, 1:30, 1:90, and 1:270
in VB/T (10 mM veronal, 150 mM NaCl, 10 mM CaCl2, 10 mM
MgCl2, 0.3% bovine serum albumin [wt/vol], 0.02% TWEEN-
20) and incubated for 30 minutes at 37°C. A standard curve
was generated using two-fold serial dilutions of a pool of
3,000 sera obtained from blood bank donors, containing 1.5
μg/ml of MBL. Plates were washed five times with water (all
other washes were also carried out in water) and incubated for
1 hour with biotinylated monoclonal antibody C4–10 [20] for
measuring C4b deposition, at 0.25 μg/ml in TTG/Ca2+. Plates
were washed five times and incubated with polymerised
streptavidin-HRP as described above. Plates were washed
five times and colour reaction was obtained and measured as
described above. Individual results are expressed as percent-
age of the standard pool serum, which was set at 100%. Val-
ues below 10% point to severely decreased activity. In healthy
controls, 90% of individuals with a C4 deposition activity
below 10% have a functional MBL serum level of less than 0.1
μg/ml.
Alternative pathway activation is excluded by diluting the
serum at least 1:10. Classical pathway activation does not
influence the assay, because addition of monoclonal antibody
C1q-85 [21], which inhibits activation of C1q by immune com-
plexes, has no effect on the results. In addition, use of MBL-
deficient serum has never resulted in detectable levels of C4
deposition under the described conditions.
C4 deposition assay results are not influenced by a low C4
concentration in serum that can be expected in patients with
SLE. Serum of two healthy donors was tested in a dilution
curve in the presence of a constant dilution of 200 ng/ml nat-
ural purified human MBL (a kind gift from Inga Laursen, Stat-
ens Serum Institute, Copenhagen, Denmark). C4 deposition is
reduced at C4 values below 0.001 g/l. Because sera with low
C4 deposition (<10%) are evaluated at a 1:10 dilution, the
assay can be performed until a minimal C4 concentration of
0.01 g/l (Figure 1).
Antibodies
The monoclonal antibody to C4b (anti-C4–10) was generated
by fusing spleen cells from mice immunised with native C4
with the mouse myeloma cell line SP2/0 [20]. CLB-MBL/1
was obtained by a fusion of spleen cells from a mouse immu-
nised with natural MBL, purified from Cohn fraction III (San-
quin) as previously described by Kilpatrick [22]. Specificity for
MBL was shown on Western blot. Affinity for the carbohy-
drate-binding domain was concluded from its ability to inhibit
binding of MBL to mannan (data not shown).
Assessment of MBL pathway activation
MBL pathway activation was assessed by an enzyme-linked
immunosorbent assay technique that measures the complete
MBL pathway activity in serum, starting with binding of MBL to
mannan, and was detected with a specific monoclonal anti-
body against C5b-9, as described previously [23]. To prevent
contribution of the classical pathway in this assay, an antibody
against C1q is added to the reaction mixture [23]. Functional
activity of the MBL pathway was expressed as percentage of
a standard consisting of pooled human serum set at 100%.
Decreased functional activity of the MBL pathway was defined
as functional activity of less than 10%.
Statistical analyses
Differences between groups were evaluated by Mann-Whit-
ney test; the following subgroups were considered: SLE
patients with one or more major infections versus SLE patients
without major infections, SLE patients with one or more major
infections versus patients who experienced minor infections
only, and SLE patients with one or more major infections ver-
sus SLE patients without any infections. Correlations between
Figure 1
Dependence of C4 deposition assay on C4 serum concentration Dependence of C4 deposition assay on C4 serum concentration. C4 
deposition was measured in a dilution curve of serum of two healthy 
donors in the presence of a constant mannose-binding lectin concen-
tration of 200 ng/ml. C4 deposition becomes C4-dependent at a con-
centration below 0.001 g/l. Because sera with low C4 deposition 
(<10%) are evaluated at a dilution of 1:10, the minimal required C4 
concentration in a tested serum will be 0.01 g/l.Arthritis Research & Therapy    Vol 8 No 6    Bultink et al.
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different assays and between assays and disease activity
scores were evaluated by calculating Spearman's correlation
coefficient. Variables possibly associated with the occurrence
of infections and major infections were first examined by uni-
variate tests and subsequently by multiple regression analysis.
As a consequence of the low number of opportunistic infec-
tions since lupus onset in our patients, a further analysis of var-
iables associated with the occurrence of opportunistic
infections was not performed. The following variables were
evaluated in relationship to the occurrence of the first major
infection since lupus diagnosis by univariate analyses: disease
duration, history of lupus nephritis confirmed by renal biopsy
occurring before the first major infection, functional MBL
serum levels, activity of the MBL pathway of complement acti-
vation, use of oral corticosteroids at the moment of first major
infection, and previous use within the last 3 months before the
first major infection of the following drugs: intravenous methyl-
prednisolone, hydroxychloroquine, methotrexate, azathioprine,
and (oral and/or intravenous) cyclophosphamide. To deter-
mine which factors were significantly associated with infec-
tions and major infections, the demographic, clinical, and
therapy variables with a p value of less than 0.2 in the univari-
ate analyses and variables with supposed clinical relevance
were entered into the respective multiple regression analyses.
The multiple regression models were refined by tentatively
adding to the (almost) final model single variables initially not
included in the model, so as to check once more whether
these variables could indeed be missed. A two-sided p value
of less than or equal to 0.05 was considered statistically sig-
nificant. The software used was the Statistical Package for
Social Sciences for Windows, version 13.0 (SPSS Inc., Chi-
cago, IL, USA).
Results
Patient characteristics
The demographic, clinical, and therapy characteristics of the
103 patients with SLE are shown in Table 1. The majority of
the patients were female Caucasians with a mean disease
duration of ± 7 years. The ethnic backgrounds of the remain-
ing 23% of patients were Asiatic (11%), negroid (8%), Medi-
terranean (3%), and other (1%). The disease activity and
organ damage index were modest in most patients at the time
of inclusion. Most patients had been treated with corticoster-
oids and hydroxychloroquine in the past. At the moment of
inclusion, half of the patients were on treatment with both cor-
ticosteroids and hydroxychloroquine and 16% were treated
with azathioprine.
Functional MBL serum levels
The median functional MBL serum level in the patients with
SLE (1.4 μg/ml, range 0.04 to 7.60 μg/ml) was comparable
with that in 100 healthy laboratory workers (1.1 μg/ml, range
0.02 to 11.2 μg/ml). The prevalence of severely decreased
MBL levels (<0.05 μg/ml) was similar to that of healthy labora-
tory workers (13% and 14%, respectively).
Complement C4 deposition and MBL pathway activity
As shown in Table 1, the median C4 deposition in patients
with SLE was 71% versus 114% in the healthy controls and
was less than 10% of the activity of the standard in 21% of the
patients with SLE versus 16% in healthy controls. The median
functional activity of the MBL pathway in patients with SLE
was 16% versus 56% in 120 healthy controls, and functional
activity of the MBL pathway was less than 10% of the activity
of the standard in 43% of the patients with SLE versus 28%
in healthy controls (Table 1).
Correlations between functional MBL level, biological 
activity of MBL, complement C4 deposition, and disease 
activity in patients with SLE
Both MBL pathway activation and C4 deposition were corre-
lated to MBL serum levels (r = 0.75 and r = 0.66, respectively).
In addition, C4 deposition was correlated to MBL pathway
activity (r = 0.77, all correlations p = 0.0001 or less). C4 levels
were poorly correlated to MBL pathway activity and C4 depo-
sition (r = 0.2, p = 0.047 and r = 0.26, p = 0.009, respec-
tively). MBL pathway activity was poorly correlated to C3 level
(r = 0.2, p = 0.046). No consistent associations between func-
tional MBL activity, measured by the three assays, and SLEDAI
(systemic lupus erythematosus disease activity index) or
ECLAM (European consensus lupus activity measurement)
disease activity scores were found (data not shown).
Infectious episodes
Fifty-one patients with SLE (50%) had suffered at least one
infectious episode since lupus onset. The number of infections
in a single patient ranged from zero to nine, and the mean (±
standard deviation) number of infections was 1.1 (± 1.7). A
total of 115 infectious episodes were documented, of which
37% were major infections. As shown in Table 2, the most
common locations of infections were skin and mucosa (29%),
lower respiratory tract (22%), upper respiratory tract (14%),
genital (11%), gastrointestinal tract (9%), and systemic (7%).
The most common infection was Herpes zoster skin infection
(16%). Microorganisms were isolated in 50% of the infectious
episodes: bacteria (45%), viruses (38%), and yeasts (12%).
Twenty-three patients had a total of 42 major infections. These
were most commonly located in the lower respiratory tract
(31%), systemic (21%), genital tract (10%), and skin and
mucosa (10%). In cases in which the causal microorganism
could be identified (57%), 71% proved bacterial, 17% viral,
4% fungal, and 4% a combination of viral and fungal infec-
tions. Staphylococcus aureus was the most frequent isolate
(17%). Five patients had an opportunistic infection: oesopha-
geal infection caused by Candida albicans (2), pneumonia
due to Klebsiella pneumoniae (1), sinusitis due to Aspergillus
fumigatus (1), and one sepsis caused by Cytomegalovirus and
C. albicans.Available online http://arthritis-research.com/content/8/6/R183
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Table 1
Demographic, clinical, and therapy variables
Variables All patients (n = 
103)
Healthy controls
Demographic variables
Female gender, percentage 91
Caucasian race, percentage 77
Age, years 41 ± 13
Comorbidity
Diabetes mellitus, percentage 4.9
Clinical and laboratory variables
Disease duration, years 6.8 ± 4
SLEDAI 4.7 ± 4
ECLAM 3.1 ± 1.6
SLICC/ACR damage index 1.4 ± 1.9
Previous biopsy proven lupus nephritis, percentage 31.1
Creatinine clearance <70 ml/minute, percentage 18
Proteinuria, percentage 13.6
Leucopoenia ever, percentage 36.9
Functional MBL serum level, median (range) μg/ml 1.4 (0.04–7.60) 1.1 (0.0–11.2)
Functional MBL serum level <0.05 μg/ml, percentage 13 14
MBL-induced C4 deposition on mannan, median (range) percentage 71 (1.1–399) 114 (3–494)
MBL-induced C4 deposition on mannan <10%, percentage 21 16
Functional activity of the MBL pathway, median (range) percentage 16 (0.1–119) 56 (0–133)
Functional activity of the MBL pathway <10%, percentage 43 28
C3 levels in serum, median (range) g/l 0.86 (0.06–1.70) (0.88–2.01)
C4 levels in serum, median (range) g/l 0.13 (0.07–0.35) 0.21 (0.11–0.61)
Therapy variables
Oral corticosteroids
Ever user, percentage 81
Current user, percentage 52
Duration of corticosteroid use in ever users, months 63 ± 70
Actual prednisone dose if >0 mg/day, mg 13 ± 12
Intravenous methylprednisolone use ever, percentage 15
Hydroxychloroquine use ever, percentage 87
Azathioprine use ever, percentage 37
Methotrexate use ever, percentage 14
Cyclophosphamide (oral and/or intravenous) use ever, percentage 13
Except where indicated otherwise, values are presented as the mean ± standard deviation. ECLAM, European consensus lupus activity 
measurement (range 0 to 10) [35]; MBL, mannose-binding lectin; SLEDAI, systemic lupus erythematosus disease activity index (range 0 to 105) 
[36]; SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology [37].Arthritis Research & Therapy    Vol 8 No 6    Bultink et al.
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Variables associated with major infectious episodes
Univariate analyses
Results of univariate analyses of potential risk factors for major
infections are shown in Table 3. Functional MBL serum levels
and functional activity of the MBL pathway of complement acti-
vation were not different between SLE patients with major
infections and those without major infections. As expected,
SLE patients who had suffered at least one major infection
since lupus diagnosis had a significantly longer mean (±
standard deviation) disease duration in comparison with SLE
patients who never had a major infection. Furthermore, the per-
centage of SLE patients with a previous SLE glomerulonephri-
tis was significantly higher in SLE patients who had major
infections than in SLE patients without major infections. The
median serum creatinine level in SLE patients at the moment
of the first major infection (74 μmol/l, range 45 to 389 μmol/l)
was comparable with that in SLE patients without major infec-
tions (82 μmol/l, range 65 to 154 μmol/l). Prevalence of
hydroxychloroquine use within the last 3 months before the
first major infection was significantly lower than the prevalence
of hydroxychloroquine use ever in SLE patients without a major
infection (p = 0.0001).
Multiple regression analyses
As shown in Table 4, disease duration was significantly posi-
tively associated and hydroxychloroquine use was significantly
negatively associated with the occurrence of the first major
infection in a multiple regression analysis that included the fol-
lowing variables: disease duration at follow-up; previous lupus
nephritis; use of hydroxychloroquine, intravenous methylpred-
nisolone, and intravenous cyclophosphamide within the last 3
months before the first major infection; use of each of these
drugs ever in case no major infection occurred (as independ-
ent variables); and first major infection (as dependent varia-
ble). None of the other variables investigated demonstrated a
significant contribution to this model.
Discussion
Our patients with SLE frequently suffered from major infec-
tions, but we found no association between functional activity
of the MBL pathway and the occurrence of infection.
Strengths of our study include a high number of clinically rele-
vant events and to our knowledge the first attempt to study
functional MBL in SLE patients at risk for infection.
Functional activity of the MBL pathway in serum not only is
determined by mutations in the gene encoding MBL, but also
is influenced by promoter polymorphisms. Moreover, biologi-
cal activity of MBL also depends on MASP activity and envi-
ronmental factors can influence MBL levels in serum [16,24].
MBL is a weak acute-phase reactant [12,25], and circulating
MBL levels were found to increase only 1.5- to 3-fold in non-
SLE patients during an acute-phase reaction [25]. No
increase was observed in individuals who were homozygous
or compound heterozygous for MBL mutant alleles [26], and
therefore quite stable MBL levels are present in individuals.
For these reasons, functional MBL activity is thought to be a
better estimate of the in vivo situation than nucleic acid substi-
tutions determining genotypes when evaluating the role of the
MBL pathway of complement activation in relation to the
occurrence of infections in SLE.
In the present study, functional MBL activity was measured by
three assays. None of these assays showed an association
Table 2
Anatomic site of infections (n = 115) and isolated microorganisms in 103 patients with systemic lupus erythematosus
Anatomic site of infections (total number) Microorganism
Skin and mucosa (33) Herpes zoster (18), Staphylococcus aureus (1), Candida albicans (2), 
unidentified (12)
Lower respiratory tract (25) S. aureus (2), Klebsiella pneumoniae (1), Haemophilus influenzae (1), 
Respiratory syncytial virus (1), unidentified (20)
Upper respiratory tract (16) Herpes simplex (2), Aspergillus fumigatus (1), unidentified (13)
Genital (13) Chlamydia trachomatis (3), C. albicans (3), Trichomonas vaginalis (1), 
Gardnerella vaginalis (1), Human papillomavirus (1), Bacteroides 
fragilis (1), unidentified (3)
Gastrointestinal tract (10) Salmonella typhi (3), Campylobacter jejuni (2), C. albicans (2), 
unidentified (3)
Systemic (8) S. aureus (5), Streptococcus group A (1), Cytomegalovirus and C. 
albicans (1), unidentified (1)
Musculoskeletal (4) Osteomyelitis by S. aureus (1), septic arthritis of knee prosthesis by S. 
aureus (1), osteomyelitis by unidentified microorganism (2)
Upper urinary tract (3) Unidentified (3)
Other (3) Pasteurella (axillary abscess), Streptococcus group A (axillary and 
cervical abscess), unidentified (post-operative abdominal abscess)
Microorganisms were isolated in 57 (50%) of the 115 infections.Available online http://arthritis-research.com/content/8/6/R183
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between deficient MBL activity and the occurrence of infec-
tions or major infections in patients with SLE. The prevalence
(13%) of severe MBL deficiency in SLE patients, defined as
MBL serum levels of less than 0.05 μg/ml, was similar to that
in healthy laboratory workers. Functional MBL level, biological
activity of MBL, and complement C4 deposition assays were
significantly correlated. However, the prevalence of decreased
C4 deposition (21%) and decreased MBL pathway activity in
43% of the patients with SLE was higher than the prevalence
of decreased MBL serum levels in patients with SLE. As
Table 3
Potential risk factors for the first major infection in 103 patients with SLE
= 1 major infection (n = 23) No major infection (n = 80) p value
Laboratory variables
Functional MBL serum level, μg/
mla
1.60 (0.04–7.00) 1.40 (0.04–7.60) 0.316
Functional MBL serum level <0.05 
μg/ml
2/23 (9%) 11/80 (14%) 0.522
MBL-induced C4 deposition on 
mannan, percentagea
64.8 (3.4–400) 71.1 (1.1–400) 0.550
MBL-induced C4 deposition on 
mannan <10%
5/23 (22%) 16/80 (20%) 0.856
MBL pathway activity, 
percentagea
14.1 (0.1–111) 17.3 (0.1–119) 0.806
MBL pathway activity <10% 10/23 (44%) 34/80 (43%) 0.934
Clinical variables
Disease duration at follow-up, 
years
12.5 ± 7.4 5.1 ± 5.7 0.0001
Previous SLE glomerulonephritis 10/23 (44%) 10/80 (10%) 0.001
Treatment variables Use <3 months before the first 
major infection
Previous use ever since lupus 
diagnosis
Oral corticosteroids 17/23 (74%) 41/80 (51%) 0.916
Intravenous methylprednisolone 5/23 (22%) 9/80 (11%) 0.204
Hydroxychloroquine 6/23 (26%) 70/80 (88%) 0.0001
Methotrexate 0/23 (0%) 9/80 (11%) 0.094
Azathioprine 8/23 (35%) 21/80 (26%) 0.424
Oral cyclophosphamide 1/23 (4%) 1/80 (1%) 0.373
Intravenous cyclophosphamide 4/23 (17%) 4/80 (5%) 0.065
Except where indicated otherwise, values are presented as the mean ± standard deviation. aValues are presented as the median (range). MBL, 
mannose-binding lectin; SLE, systemic lupus erythematosus.
Table 4
Multivariate analysis of the first major infection (dependent variable) and clinical and therapy variables (independent variables)
Variables Odds ratio 95% confidence interval p value
Disease duration 1.18 1.07–1.31 0.001
Previous SLE glomerulonephritis 3.92 0.71–21.56 0.116
Hydroxychloroquinea 0.05 0.01–0.23 0.0001
Intravenous methylprednisolonea 2.18 0.36–13.13 0.392
Intravenous cyclophosphamidea 0.35 0.03–3.87 0.390
aUse within the last 3 months before the first major infection or previous use since lupus diagnosis if no major infection. SLE, systemic lupus 
erythematosus.Arthritis Research & Therapy    Vol 8 No 6    Bultink et al.
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expected, both C4 and C3 levels were lower in SLE patients
than in healthy controls. However, correlations between C4 or
C3 and C4 deposition and MBL pathway activity were very
low. MBL-induced complement activity was correlated to MBL
levels in patients and healthy controls. Our findings are in con-
trast to a previous study in which MBL-induced C4 deposition
was associated with plasma C4 levels in healthy controls and
patients with SLE [27]. In that study, MBL levels were corre-
lated to C4 deposition in healthy controls but not in patients
with SLE, suggesting a high sensitivity of that assay for C4 lev-
els. Our C4 deposition assay is dependent primarily on func-
tional MBL plasma levels in both healthy controls and patients
with SLE, and C4 is not a limiting factor until very low concen-
trations of 0.01 g/l in healthy controls. Although all patients
with SLE had levels above the threshold, dysfunction of C4 or
the presence of complement inhibitors in SLE plasma cannot
be excluded, because MBL-induced complement activity is
reduced in our patients. Furthermore, additional consumption
of complement factors other than C4 may be relevant because
we observed a higher frequency of deficient patients in the
MBL pathway activity assay compared with the C4 deposition
assay. Further studies are needed to investigate the role of the
several complement deficiencies, dysfunction, inhibitors, and
consumption.
To exclude an influence of very low C4 serum levels on both
C4 deposition and MBL pathway activity assays, subanalyses
of the association between laboratory variables and the occur-
rence of infections and major infections were performed after
exclusion of SLE patients with C4 serum levels of less than or
equal to 0.1 g/l (n = 28). In these subanalyses, C4 deposition
assay and MBL pathway activity assay were not associated
with infections or major infections, either in univariate and mul-
tiple regression analyses (data not shown).
When functional MBL activity with respect to the severity of
infections was analysed, no significant differences were found
between median values of functional MBL serum level, C4
deposition, and MBL pathway activity in three subgroups of
patients: SLE patients with one or more major infections,
patients with SLE who experienced minor infections only, and
SLE patients without any infections (Figure 2).
Associations between MBL genotype and the occurrence of
infections in patients with SLE have been reported [8-10]. In
those studies, MBL serum levels were measured as well, but
no association between low MBL serum levels and the occur-
rence of infections was demonstrated, probably because of
the inability of serologic methods used to distinguish between
functional and nonfunctional protein [28]. Unfortunately, no
DNA is available from our patient cohort and for this reason we
cannot correlate MBL genotype and risk of infections. As far
as data are available, differences in clinical and epidemiologi-
cal characteristics of the study patients are unlikely to be
responsible for the discrepancy between the results of the
Figure 2
Mannose-binding lectin (MBL) serum level, C4 deposition, and MBL  pathway activity Mannose-binding lectin (MBL) serum level, C4 deposition, and MBL 
pathway activity. Functional MBL activity measured by three assays in 
all patients with systemic lupus erythematosus (SLE; n = 103), a sub-
group of SLE patients without infections (SLEno; n = 52), a subgroup 
of patients with SLE who had minor infections only (SLEmin; n = 28), a 
subgroup of SLE patients with one or more major infections (SLEmaj; n 
= 23), and healthy controls. (a) MBL serum levels. (b) Complement C4 
deposition. (c) MBL pathway activity. Each datapoint represents one 
patient. Bars show the median values. No significant differences were 
found between the median functional MBL activity of all patients with 
SLE and each of the subgroups or between the subgroups, as meas-
ured with three assays (data not shown).Available online http://arthritis-research.com/content/8/6/R183
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present study and previous studies [8-10], except for the dif-
ferent racial background of the study patients in the Japanese
study [10]. Another explanation for the discrepancy between
the genotypic and the phenotypic data could be that unidenti-
fied linkages between mutations or polymorphisms in the MBL
gene with mutations or polymorphisms in other genes might
influence the genetic approach.
Despite the use of new treatment strategies to improve the
clinical outcome in patients with SLE, the importance of
infections as a cause of morbidity and mortality in SLE has not
changed in the past decades. Defects of immune defence and
treatment with corticosteroids and immunosuppressive agents
are supposed to play a role in the pathogenesis of infections
in SLE [3], but the mechanisms underlying the increased infec-
tion rate in SLE are not fully understood. Our study demon-
strates the occurrence of at least one infectious episode since
lupus diagnosis in 50% of patients with SLE, and this high
infection rate is confirmed by other studies reporting infectious
complications in up to 45% of SLE patients in case series
[1,29]. The spectrum of infections found in our study is in line
with other studies in patients with SLE, which report a broad
spectrum of infections caused predominantly by community-
acquired bacteria [1,29,30]. The severity of infections found in
other studies in patients with SLE [1,30] is confirmed by our
study, which shows a third of the infections in patients with
SLE to be major infections for which hospital admission was
required. Furthermore, the high incidence of Herpes zoster
infection, occurring at least one time in 14% of the patients, is
in line with other studies in patients with SLE [1,31].
With respect to major infections, use of immunosuppressive
medication and use of corticosteroids were not associated
with the occurrence of the first major infection in our patients
in the best multiple logistic regression model. This finding is in
line with a previous study on major infections in SLE patients
in the Hopkins Lupus Cohort [32].
Renal insufficiency is a possible risk factor for infections. How-
ever, no such association was found in our study. The
presence of prior SLE glomerulonephritis was not significantly
associated with the occurrence of the first major infection in
the best multiple logistic regression model. Moreover, the
median serum creatinine level at the moment of the first major
infection was similar to that in SLE patients without major
infection.
Our study demonstrated a significant negative association
between hydroxychloroquine use and the occurrence of major
infections. This finding might be explained by the predominant
use of hydroxychloroquine in the treatment of patients with
mild lupus disease activity and not by the antimicrobial proper-
ties of hydroxychloroquine. Antimalarials act against patho-
genic organisms that are very uncommon in Western Europe.
Limitations of the present study are the racial and socioeco-
nomic backgrounds of the study population. As a conse-
quence of the rather high percentage of Caucasians in the
study population, the associations found in the present study
may not be generalised to lupus cohorts of different racial
background. However, the disease severity in our study popu-
lation appears to be comparable to that in other large multi-
ethnic SLE cohorts with respect to current corticosteroid use
[33,34], prevalence of renal disease [1,30,33,34], mean organ
damage index [1,34], and mean disease activity score [30,33],
suggesting that race may not have had an important influence
on our conclusions. Socioeconomic status, a factor influenc-
ing disease severity and prognosis in patients with SLE, was
not assessed in the present study. Therefore, the results of our
study may not be generalised to SLE cohorts of different soci-
oeconomic background.
Conclusion
The results of the present study emphasise that infection
imposes a serious burden on patients with SLE. Although
defects in the complement system have been suggested to be
partially responsible for the high infection rate in patients with
SLE, the results of our study suggest that deficiency of func-
tional MBL activity does not play a role in the susceptibility to
infections or major infections.
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